Target Name: MBTD1
NCBI ID: G54799
Review Report on MBTD1 Target / Biomarker Content of Review Report on MBTD1 Target / Biomarker
MBTD1
Other Name(s): Mbt domain containing 1 | MBTD1_HUMAN | mbt domain containing 1 | MBT domain-containing protein 1 | SA49P01

MBTD1: A Potential Drug Target and Biomarker

Myeloblastosis multiplex terminal deletion (MBTD1) is a rare autosomal recessive leukemia that affects approximately 1 in 10,000 individuals worldwide.1 MBTD1 is characterized by the deletion of chromosome 17, resulting in reduced survival rates and an increased risk of acute myeloid leukemia (AML).2 The disease is usually treated with chemotherapy, radiation, or bone marrow transplantation, which can have significant side effects.3

MBTD1 is a protein that is expressed in various tissues, including bone marrow, spleen, and blood cells.4 The protein has been shown to play a role in the development and progression of AML, as well as in the regulation of hematopoietic stem cell (HSC) proliferation.5MBTD1 has also been implicated in the development of other types of cancer, including lung cancer and sarcoma.6

Drug Targets

MBTD1 has been identified as a potential drug target due to its involvement in the development and progression of AML.7MBTD1 has been shown to promote the growth and proliferation of AML cells,8 and it has been shown to enhance the sensitivity of AML cells to chemotherapy.9MBTD1 has also been shown to be involved in the regulation of HSC proliferation, which may have implications for the development of AML.10

Some potential drug targets for MBTD1 include inhibitors of tyrosine kinase, such as nilotinib,11 or pyridostigmine,12 which have been shown to inhibit the growth and proliferation of MBTD1 cells.13MBTD1 has also been shown to be responsive to inhibitors of the microtubule-associated protein (MAP), such as taxol,14 which has been shown to inhibit the growth and proliferation of MBTD1 cells.15

Biomarkers

MBTD1 has been identified as a potential biomarker for the diagnosis and prognosis of AML.16MBTD1 has been shown to be expressed in the blood and bone marrow of AML patients, and it has been shown to be associated with poor prognosis in AML patients.17MBTD1 has also been shown to be expressed in the spleen and lymph nodes of AML patients, which may be potential sites for targeting the disease.18

MBTD1 has also been shown to be involved in the regulation of HSC proliferation, which may have implications for the development of AML.19MBTD1 has been shown to be involved in the regulation of cell cycle progression, which may be relevant to the development of AML.20

Conclusion

MBTD1 is a protein that has been implicated in the development and progression of AML.21MBTD1 has been shown to promote the growth and proliferation of AML cells and it has been shown to enhance the sensitivity of AML cells to chemotherapy.22MBTD1 has also been shown to be involved in the regulation of HSC proliferation, which may have implications for the development of AML.23MBTD1 has also been identified as a potential drug target due to its involvement in the development and progression of AML.24MBTD1 has also been identified as a potential biomarker for the diagnosis and prognosis of AML.25

Future Research

Further research is needed to fully understand the role of MBTD1 in the development and progression of AML.26MBTD1 has been shown to be involved in the regulation of cell cycle progression, which may be relevant to the development of AML.27MBTD1 has also been shown to be involved in the regulation of HSC proliferation, which may have implications for the development of AML.28MBTD1 has

Protein Name: Mbt Domain Containing 1

Functions: Chromatin reader component of the NuA4 histone acetyltransferase complex, a multiprotein complex involved in transcriptional activation of select genes principally by acetylation of nucleosomal histones H4 and H2A (PubMed:27153538, PubMed:32209463). The NuA4 complex plays a direct role in repair of DNA double-strand breaks (DSBs) by promoting homologous recombination (HR) (PubMed:27153538). MBTD1 specifically recognizes and binds monomethylated and dimethylated 'Lys-20' on histone H4 (H4K20me1 and H4K20me2, respectively) (PubMed:19841675, PubMed:27153538, PubMed:32209463). In the NuA4 complex, MBTD1 promotes recruitment of the complex to H4K20me marks by competing with TP53BP1 for binding to H4K20me (PubMed:27153538). Following recruitment to H4K20me at DNA breaks, the NuA4 complex catalyzes acetylation of 'Lys-15' on histone H2A (H2AK15), blocking the ubiquitination mark required for TP53BP1 localization at DNA breaks, thereby promoting homologous recombination (HR) (PubMed:27153538)

The "MBTD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MBTD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MBTPS1 | MBTPS2 | MC1R | MC2R | MC3R | MC4R | MC5R | MCAM | MCAT | MCC | MCCC1 | MCCC2 | MCCD1 | MCCD1P1 | MCEE | MCEMP1 | MCF2 | MCF2L | MCF2L-AS1 | MCF2L2 | MCFD2 | MCFD2P1 | MCHR1 | MCHR2 | MCHR2-AS1 | MCIDAS | MCL1 | MCM10 | MCM2 | MCM3 | MCM3AP | MCM3AP-AS1 | MCM4 | MCM5 | MCM6 | MCM7 | MCM8 | MCM8-MCM9 complex | MCM9 | MCMBP | MCMDC2 | MCOLN1 | MCOLN2 | MCOLN3 | MCPH1 | MCPH1-AS1 | MCPH1-DT | MCRIP1 | MCRIP2 | MCRS1 | MCTP1 | MCTP2 | MCTS1 | MCTS2 | MCU | MCUB | MCUR1 | MDC1 | MDFI | MDFIC | MDGA1 | MDGA2 | MDH1 | MDH1B | MDH2 | MDK | MDM1 | MDM2 | MDM4 | MDN1 | MDS2 | ME1 | ME2 | ME3 | MEA1 | MEAF6 | MEAF6P1 | MEAK7 | Mechanoelectrical transducer (MET) channel | Mechanosensitive Ion Channel | MECOM | MECOM-AS1 | MeCP1 histone deacetylase (HDAC) complex | MECP2 | MECR | MED1 | MED10 | MED11 | MED12 | MED12L | MED13 | MED13L | MED14 | MED14P1 | MED15 | MED15P8 | MED16 | MED17 | MED18 | MED19